StockWatch
·

Monte Rosa Therapeutics, Inc. Q1 FY26 Results

GLUEQ1 FY26 Results
Filing
MetricValue ($ M)Q1 FY25
Revenue4.2195.0%
Total Income4.2195.0%
Expenditure54.2432.6%
PBT-44.45193.2%
Net Profit-44.50194.9%
OPM—
NPM—
EPS—
View full financials

Monte Rosa Therapeutics Reports Q1 2026 Financial Results and Business Updates

07 May 2026 · 7 May, 4:38 pm

Summary

Monte Rosa Therapeutics reported its first quarter 2026 financial results, with a net loss of $44.5 million compared to a net income of $46.9 million in the same quarter of the previous year. Collaboration revenue decreased to $4.2 million from $84.9 million year-over-year, while R&D expenses increased to $44.1 million from $32.2 million. The company's cash position remains strong at $671 million, expected to fund operations into 2029. Monte Rosa is advancing multiple programs through the clinic, with Phase 2 trial initiations expected for several programs.

Key Highlights

  1. 1

    Monte Rosa Therapeutics reported cash, cash equivalents, restricted cash, and marketable securities of $671 million as of March 31, 2026, expected to support operations into 2029.

  2. 2

    The company expects to initiate multiple MRT-8102 Phase 2 studies, including in patients with elevated atherosclerotic risk in H2 2026.

  3. 3

    Collaboration revenue for the first quarter of 2026 was $4.2 million, compared to $84.9 million for the first quarter of 2025.

  4. 4

    Research and Development expenses for the first quarter of 2026 were $44.1 million, compared to $32.2 million for the first quarter of 2025.

  5. 5

    Net loss for the first quarter of 2026 was $44.5 million, compared to $46.9 million net income for the first quarter of 2025.

  6. 6

    The company plans to initiate a Phase 2 study of MRT-2359 in combination with apalutamide in mCRPC in Q3 2026.

  7. 7

    Interim clinical data from GFORCE-1 trial of NEK7-directed MGD MRT-8102 demonstrated profound CRP reductions in subjects with elevated CVD risk.

Management Comments

M

Markus Warmuth

“We continue to make excellent progress advancing multiple programs through the clinic, with all three of our clinical-stage programs approaching Phase 2 trial initiations. Building on interim clinical data for our NEK7-directed MGD MRT-8102 demonstrating rapid, deep, and durable reductions in systemic inflammation, we expect to read out the GFORCE-1 study in subjects with elevated cardiovascular disease (CVD) risk this year, and to initiate three Phase 2 studies, starting in H2 2026, in diseases driven by the NLRP3/IL-1/IL-6 pathway. We also expect our collaborator Novartis to initiate multiple Phase 2 studies of our VAV1-directed MGD MRT-6160 in immune-mediated diseases this year. In addition, our oncology programs are also progressing rapidly, in particular with a Phase 2 study initiation of MRT-2359 in metastatic castration-resistant prostate cancer (mCRPC) patients with androgen receptor (AR) mutations planned for Q3 2026, following the encouraging Phase 1/2 data we presented at ASCO GU.”

Informational and educational content only. Not investment advice.